These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

884 related articles for article (PubMed ID: 22089421)

  • 1. Gastrointestinal stromal tumours: origin and molecular oncology.
    Corless CL; Barnett CM; Heinrich MC
    Nat Rev Cancer; 2011 Nov; 11(12):865-78. PubMed ID: 22089421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular research directions in the management of gastrointestinal stromal tumors.
    Tarn C; Godwin AK
    Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
    Kim EJ; Zalupski MM
    J Surg Oncol; 2011 Dec; 104(8):901-6. PubMed ID: 22069175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.
    Zhi X; Zhou X; Wang W; Xu Z
    PLoS One; 2013; 8(11):e79275. PubMed ID: 24223922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal stromal tumor and its targeted therapeutics.
    Dupart J; Zhang W; Trent JC
    Chin J Cancer; 2011 May; 30(5):303-14. PubMed ID: 21527063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.
    Wang CM; Huang K; Zhou Y; Du CY; Ye YW; Fu H; Zhou XY; Shi YQ
    J Cancer Res Clin Oncol; 2010 Jul; 136(7):1065-71. PubMed ID: 20043176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
    Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
    Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
    Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
    Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Translational research and diagnosis in GIST].
    Wardelmann E
    Pathologe; 2012 Nov; 33 Suppl 2():273-7. PubMed ID: 22968735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.
    Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY
    Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit.
    Pelczar P; Zibat A; van Dop WA; Heijmans J; Bleckmann A; Gruber W; Nitzki F; Uhmann A; Guijarro MV; Hernando E; Dittmann K; Wienands J; Dressel R; Wojnowski L; Binder C; Taguchi T; Beissbarth T; Hogendoorn PC; Antonescu CR; Rubin BP; Schulz-Schaeffer W; Aberger F; van den Brink GR; Hahn H
    Gastroenterology; 2013 Jan; 144(1):134-144.e6. PubMed ID: 23041331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.
    Miranda C; Nucifora M; Molinari F; Conca E; Anania MC; Bordoni A; Saletti P; Mazzucchelli L; Pilotti S; Pierotti MA; Tamborini E; Greco A; Frattini M
    Clin Cancer Res; 2012 Mar; 18(6):1769-76. PubMed ID: 22282465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The GIST paradigm: lessons for other kinase-driven cancers.
    Antonescu CR
    J Pathol; 2011 Jan; 223(2):251-61. PubMed ID: 21125679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
    Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
    PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib treatment for gastrointestinal stromal tumour (GIST).
    Lopes LF; Bacchi CE
    J Cell Mol Med; 2010 Jan; 14(1-2):42-50. PubMed ID: 19968734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular and genetic features of gastrointestinal stromal tumors (GIST)].
    Buleje S J; Yábar B A; Guevara-Fujita M; Fujita R
    Rev Gastroenterol Peru; 2012; 32(4):394-9. PubMed ID: 23307090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503.
    Liu NN; Ohkouchi M; Hashikura Y; Kajimoto N; Matsuda I; Isozaki K; Toh Y; Takahashi T; Nishida T; Hirota S
    Lab Invest; 2013 May; 93(5):502-7. PubMed ID: 23459373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.